TORL BioTherapeutics Names New CFO and CMO Ahead of Late-Stage Push
Los Angeles – October 16, 2026 -- TORL BioTherapeutics has appointed Sandip Kapadia as Chief Financial Officer, a executive who has raised more than $2 billion in public capital for emerging biotechnology companies, and Eric Sievers, M.D., as Chief Medical Officer, completing a year-long expansion of its leadership team.
TORL prepares lead antibody-drug conjugate for late-stage development
The clinical-stage oncology company is advancing its antibody-based portfolio toward late-stage development and potential commercialization. Its lead asset, ixotatug vedotin (Ixo-V), is being evaluated in platinum-resistant ovarian cancer and other cancers that express CLDN6, including germ cell tumors, and in various combinations. Ixo-V has FDA Fast Track designation.
TORL describes Ixo-V as the first and only antibody-drug conjugate (ADC) that selectively targets Claudin 6 (CLDN6) using a proven monomethyl auristatin E (MMAE) linker-payload construct.